

**Synthesis and characterization of analogues of the  
antimalarial alkaloid febrifugine**

**Daniel Petzer Pienaar**

A thesis submitted to the Faculty of Science,  
University of the Witwatersrand,  
Johannesburg,  
in fulfilment of the requirements for the degree of  
Doctor of Philosophy

July 2005

## **DECLARATION**

I declare that this thesis is my own, unaided work. It is being submitted for the degree of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination in any other university.

11 July 2005

## ABSTRACT

The subject of this thesis is the development of a potentially simple, general and economical synthetic protocol for the potent antimalarial alkaloid febrifugine (**1**) and its analogues. In Chapter 1, the interesting history of **1**, which includes a description of several reported total syntheses of **1**, is discussed. Natural products derived from **1**, as well as promising synthetic derivatives that display good antimalarial activity, are also discussed. The structure-activity relationships determined to date for **1** and its derivatives are presented in order to substantiate the need for the development of new synthetic strategies towards derivatives of **1** and its 3''-unsubstituted analogue, ( $\pm$ )-deoxyfebrifugine (**14**).

A brief overview of the general strategies used in the Organic Chemistry Group at the University of the Witwatersrand for the synthesis of alkaloids is given in Chapter 2. The Eschenmoser sulfide contraction reaction between a thiolactam and an  $\alpha$ -bromocarbonyl compound results in the formation of a vinylogous amide (or "enaminone") product, which can be further manipulated to produce commonly encountered alkaloidal molecular skeletons. The chosen approach to **1** is based on reaction between the pivotal bromide 3-(3-bromo-2-oxopropyl)quinazolin-4(3*H*)-one (**105**) and suitable 3-substituted piperidine-2-thiones.

A series of model studies, described in Chapter 3, was performed in order to test the feasibility of the synthetic strategy. These studies resulted in a new preparation of the key bromide **105** and a new and efficient synthesis of ( $\pm$ )-deoxyfebrifugine (**14**). Enaminone analogues derived from five-, seven-, eight-, nine- and thirteen-membered thiolactams were also prepared for comparison. An interesting difference in the sensitivity of the five- and six-membered model cyclic vinylogous amides towards reducing agents was observed. Whereas three piperidine analogues of **14** could be prepared in high yields by the chemoselective hydrogenation of six-membered cyclic vinylogous amide precursors, the five-membered analogues either reacted non-selectively under various standard hydrogenation conditions, or resisted reduction entirely.

An extension of the approach towards the synthesis of a 3''-amino analogue of febrifugine (**1**) from L-ornithine is discussed in Chapter 4. Several 3-aminated piperidin-2-ones and thiones were prepared, but the subsequent enaminones were stable and characterizable only when the piperidinylidene ring nitrogen was alkylated. However, chemoselective reduction of the enaminone C=C bond in 3-{{(E)-3-[(3S)-3-(tert-butoxycarbonylamino)-1-(4-methoxybenzyl)piperidin-2-ylidene]-2-oxopropyl}-quinazolin-4(3H)-one (**221**), an interesting 3-acylamino dehydro analogue of **1**, did not give the desired azafebrifugine, but instead yielded a 5,6,7,8-tetrahydro-1H-pyrido[3,2-c][1,2]oxazine derivative.

Several approaches to febrifugine (**1**) itself based on the successful model studies are discussed in Chapter 5. Initially, stereoselective  $\alpha$ -bromination and subsequent substitution by oxygen of piperidin-2-ones derived from the chiral auxiliary (*S*)-phenylglycinol was explored. Unexpected racemization occurred at the  $\alpha$ -position of the lactam during this route. A second approach to 3-hydroxypiperidin-2-one from L-arginine was also problematic. Finally, the utility of  $\alpha$ -hydroxylation methodology (including Davis methodology) on *N*-substituted piperidin-2-ones was explored. This route yielded a range of 3-oxygenated lactams and thiolactams, many of which displayed optical activity. The crystal structures of several 3-substituted thiolactams were determined and compared. However, attempts to apply the sulfide contraction procedure to these precursors were unsuccessful.

Some investigations designed to explore the structural differences between vinylogous amides derived from the quinazoline-containing bromide **105** and thiolactams of different ring sizes are discussed in Chapter 6. Single crystal X-ray diffraction and NMR spectral data are compared for this series of compounds, the results revealing that the enaminone group in the five-membered ring derivative 3-[(3Z)-2-oxo-3-(pyrrolidin-2-ylidene)propyl]quinazolin-4(3H)-one **155** possesses a significantly different electronic distribution to the other analogues in the series.

## ACKNOWLEDGEMENTS

I wish to express my sincere gratitude to the following people:

My parents Pine and Pettie Pienaar, to whom this thesis is dedicated, for being the outstanding people you are.

My supervisors Prof. Jo Michael and Prof. Charles de Koning, for your support and your patience, and for sharing your expertise with me.

Mr Richard Mampa, Mr Tommie van der Merwe, Mr Manuel Fernandes, Dr Dave Billing, Mr Andreas Lemmerer, Mr Denzel Sannasy, Dr E. Mabel Coyanis, Dr Andy Dinsmore and Dr Riaan Petersen, for their kind assistance and the valuable discussions during this project.

All the postgraduate students in the Organic Chemistry Group at Wits.

My family and friends whose love and support were vital to me whilst pursuing this project.

## TABLE OF CONTENTS

### CHAPTER 1: INTRODUCTION TO FEBRIFUGINE

1.1.	History of febrifugine	1
1.2.	Structural elucidation of febrifugine and isofebrifugine	4
1.3.	Other alkaloids related to febrifugine	9
1.4.	Antimalarial properties of febrifugine and its derivatives	11
1.5.	Published syntheses of febrifugine and isofebrifugine	30
1.6.	Published syntheses of ( $\pm$ )-deoxyfebrifugine	41

### CHAPTER 2: A PROPOSAL FOR A NEW SYNTHESIS OF FEBRIFUGINE

2.1.	Introduction to enamines and the Wits approach to alkaloid synthesis	47
2.2.	Strategy and aims	52

### CHAPTER 3: MODEL SYNTHETIC STUDIES

3.1.	Aims	57
3.2.	Synthesis of quinazolin-4(3 <i>H</i> )-one	57
3.3.	Synthesis of the bromide precursor, 3-(3-bromo-2-oxopropyl)-quinazolin-4(3 <i>H</i> )-one ( <b>105</b> )	59
3.4.	Synthesis of the thiolactam precursors	62
3.5.	The preparation of the model <i>N</i> -protected vinylogous amides	70
3.6.	The preparation of the model <i>N</i> -unprotected vinylogous amides	75
3.7.	Deprotection of 3-{(2 <i>E</i> )-2-[2-oxo-3-(4-oxoquinazolin-3(4 <i>H</i> )-yl)propylidene]piperidin-1-yl}propanenitrile ( <b>146</b> )	79
3.8.	Chemoselective C=C reduction of the model vinylogous amides	80
3.9.	Synthetic studies towards the azetidinylidene enaminone analogue ( <b>183</b> )	97
3.10.	Conclusion and future work	103

**CHAPTER 4: APPROACHES TOWARDS THE 3''-AMINO  
ANALOGUE OF FEBRIFUGINE**

4.1.	Background	105
4.2.	Approach without <i>N</i> -protection of the piperidine ring	108
4.3.	Approach using <i>N</i> -(4-methoxybenzyl) protection	119
4.4.	Approach using <i>N</i> -(2-methylnaphthyl) protection	125
4.5.	Conclusion	127

**CHAPTER 5: APPROACHES TOWARDS FEBRIFUGINE**

5.1.	Approach to febrifugine using a chiral auxiliary; Quirion methodology	128
5.2.	Approach to febrifugine from L-arginine	136
5.3.	Approaches to febrifugine by $\alpha$ -hydroxylation of piperidin-2-ones	152
5.4.	Conclusion	187

**CHAPTER 6: THE STRUCTURES OF CYCLIC VINYLOGOUS  
AMIDES**

6.1.	Background	188
6.2.	Crystal structures of selected model vinylogous amides	198
6.3.	Comparison of crystal structures and physical properties	211
6.4.	Comparison of torsion angles	215
6.5.	Comparison of interatomic distances and bond angles	217
6.6.	Comparison of NMR data	222
6.7.	Conclusion and future work	226

**CHAPTER 7: EXPERIMENTAL SECTION RELATING TO  
CHAPTER 3**

7.1.	Synthesis of the bromide precursor, 3-(3-bromo-2-oxopropyl)-quinazolin-4(3 <i>H</i> )-one ( <b>105</b> )	230
------	--	-----

7.2.	Synthesis of the <i>N</i> -alkyl thiolactam precursors	232
7.3.	Synthesis of the <i>N</i> -unprotected thiolactam precursors	236
7.4.	Representative procedure for the Eschenmoser sulfur extrusion reaction between pyrrolidyl or piperidyl <i>N</i> -alkyl thiolactams and 3-(3-bromo-2-oxopropyl)-4(3 <i>H</i> )-quinazolinone ( <b>105</b> )	240
7.5.	Representative procedure for the Eschenmoser sulfur extrusion reaction between pyrrolidyl or piperidyl <i>N</i> -unprotected thiolactams and 3-(3-bromo-2-oxopropyl)-4(3 <i>H</i> )-quinazolinone ( <b>105</b> )	244
7.6.	Representative procedure for the chemoselective reduction of the piperidin-2-ylidene <i>N</i> -alkyl enaminone products	248
7.7.	Chemoselective reduction of <b>101</b>	250
7.8.	Attempted synthesis of the azetidinylidene enaminone ( <b>183</b> )	251

**CHAPTER 8:           EXPERIMENTAL SECTION RELATING TO  
CHAPTER 4**

8.1.	Attempts without piperidinyl <i>N</i> -protection	255
8.2.	Attempts using <i>N</i> -(4-methoxybenzyl) as a piperidinyl <i>N</i> -protecting group	258
8.3.	Attempts using <i>N</i> -(2-methylnaphthyl) as a piperidinyl <i>N</i> -protecting group	262

**CHAPTER 9:           EXPERIMENTAL SECTION RELATING TO  
CHAPTER 5**

9.1.	Approach to febrifugine using Micouin methodology [i.e. using ( <i>S</i> )-phenylglycinol as a chiral auxiliary]	266
9.2.	Approaches to febrifugine from L-arginine	270
9.3.	Approaches to febrifugine using piperidin-2-one $\alpha$ -hydroxylation methodology	274

**REFERENCES** 289

**APPENDICES:**

(i)	Selected <sup>1</sup> H and <sup>13</sup> C NMR spectra	296
(ii)	Compact Disc containing the X-ray crystallography data, the files of which are numbered according to the compound numbers in this thesis	

## ABBREVIATIONS

Ac	acetyl	DMAP	4-( <i>N,N</i> -dimethylamino)pyridine
aq.	aqueous	DMF	<i>N,N</i> -dimethylformamide
Ar	aryl	DMSO	dimethyl sulfoxide
Bn	benzyl	E2	bimolecular elimination
Boc	<i>tert</i> -butoxycarbonyl	EC <sub>50</sub>	50% effective concentration
Bu and <i>n</i> -Bu	butyl	EI	electron impact
<i>sec</i> -Bu	<i>sec</i> -butyl	EI	electrophile
<sup>t</sup> Bu	<i>tert</i> -butyl	Et	ethyl
Bz	benzoyl	EtOAc	ethyl acetate
CAN	ceric ammonium nitrate	EWG	electron withdrawing group
cat.	catalytic	FAB	fast atom bombardment
CBz	benzyloxycarbonyl	HMDO	hexamethyldisiloxane
conc.	concentration	HMDS	1,1,1,3,3,3-hexamethyldisilazane
<i>m</i> -CPBA	<i>m</i> -chloroperoxybenzoic acid	HPLC	high pressure liquid chromatography
CS	(10-camphorsulfonyl)-oxaziridine	HR	high resolution
DBU	1,8-diazabicyclo[5.4.0]-undec-7-ene	IR	infrared
DCC	dicyclohexylcarbodiimide	LAH	lithium aluminium hydride
DCCS	(8,8-dichloro-10-camphorsulfonyl)-oxaziridine	LPS	lipopolysaccharide
DDQ	2,3-dichloro-5,6-dicyano-1,4-benzoquinone	Me	methyl
DEPC	diethyl phosphoryl cyanide	MOM	methoxymethyl
DIBAL	diisobutylaluminium hydride	MoOPH	oxodiperoxymolybdenum(pyridine)(hexamethylphosphoric

	triamide)		$S_N1$	unimolecular
MS	mass spectrometry			nucleophilic
Ms	methanesulfonyl			substitution
NAP	2-naphthylmethyl		$S_N2$	bimolecular
NBS	<i>N</i> -bromosuccinimide			nucleophilic
<i>l</i> -NMA	<i>N</i> -methyl-L-arginine			substitution
NOE	Nuclear Overhauser	TBDMS		<i>tert</i> -butyldimethylsilyl
	enhancement	TBDPS		<i>tert</i> -butyldiphenylsilyl
Nu	nucleophile	TBS		<i>tert</i> -butyldimethylsilyl
o.n.	overnight	Tf		trifluoromethane-
Pd/C	palladium on carbon			sulfonyl
Ph	phenyl	TFA		trifluoroacetic acid
PMB	<i>p</i> -methoxybenzyl	THF		tetrahydrofuran
PPA	polyphosphoric acid	TLC		thin layer
Pr	propyl			chromatography
<sup><i>i</i></sup> Pr and <i>i</i> -Pr	isopropyl	TMS		trimethylsilyl
Q	quinazolin-2-yl	Ts		<i>p</i> -toluenesulfonyl
rt	room temperature	UV		ultraviolet
s.m.	starting material			